Close

Boston Scientifics PFA system achieves efficacy and safety endpoints

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Life Sciences Sector Plan Sets UK on Global Growth Track

Main Article: UK Life Sciences Sector Plan Sets Sights...

UK Government Launches Ambitious Life Sciences Sector Plan

Government Unveils Life Sciences Roadmap for Growth and Innovation London,...

Highly Customized Treatments to Offer Specialized Care to UK

The Human Medicines Regulations 2025, which came into force...

UK Life Sciences Sector Plan Eases Startup Regulations

How the UK Life Sciences Sector Plan Reduces Regulatory...

Boston Scientific has announced the achievement of primary efficacy and safety endpoints in the ADVENT Study of the FARAPULSE Pulsed Field Ablation (PFA) System.

FARAPULSE is a nonthermal treatment, which selectively applies electric fields for ablating heart tissue in patients with atrial fibrillation (AF).

The pivotal, randomised clinical study compared the efficacy and safety of the system versus standard-of-care ablation, either cryoablation or radiofrequency, to treat patients with paroxysmal, or intermittent, AF.

Over the course of 12 months, the data indicated that the system was as effective as standard-of-care treatments, even though most physicians had only worked with thermal ablation in the past.

The prospective, multicentre trial included 607 US patients with paroxysmal AF who had earlier been unsuccessfully treated with a minimum of one anti-arrhythmic drug.

Boston Scientific global chief medical officer and senior vice-president Kenneth Stein said: “These data underscore the superior procedural efficiency of this novel technology, and real-world use continues to yield strong safety and efficacy outcomes.

“The performance of the FARAPULSE PFA System in this trial is an encouraging sign of the potential utilisation of the device in the US and we look forward to further studying the system for the treatment of patients with persistent AF in the ADVANTAGE AF clinical trial, which began enrolment earlier this year.”

 

In 2021, the company received CE Mark for the FARAPULSE PFA System. So far, it has been used to treat over 25,000 patients across the globe.

 

Latest stories

Related stories

Life Sciences Sector Plan Sets UK on Global Growth Track

Main Article: UK Life Sciences Sector Plan Sets Sights...

UK Government Launches Ambitious Life Sciences Sector Plan

Government Unveils Life Sciences Roadmap for Growth and Innovation London,...

Highly Customized Treatments to Offer Specialized Care to UK

The Human Medicines Regulations 2025, which came into force...

UK Life Sciences Sector Plan Eases Startup Regulations

How the UK Life Sciences Sector Plan Reduces Regulatory...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back